Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
复制标题
强直性脊柱炎和类风湿关节炎患者的血清硬化素水平：系统评价和荟萃分析
DOI：
10.1155/2017/9295313
复制
发表时间：
2017
影响因子：
--
通讯作者：
Shen B
中科院分区：
文献类型：
--
作者：
Shi J;Ying H;Du J;Shen B
目标。目前对AS和RA患者血清硬化蛋白水平的研究不一致。本荟萃分析旨在确定血清硬化蛋白水平与AS和RA患者的关系。方法。使用Embase、PubMed、MEDLINE和Cochrane图书馆数据库（截至2017年1月25日）收集所有相关的已发表文章。对研究进行汇总，计算95%置信区间（CI）的标准均差（SMD）。所有数据分析均使用RevMan 5.3进行。结果。本次meta分析共纳入8项AS研究，包括420例AS患者和317例健康对照（HC）； 3项RA研究，包括145例RA患者和127例HC。结果显示，AS患者（SMD = - 0.14; 95% CI = [- 0.39,0.11]; P = 0.28）和RA患者（SMD = - 0.10; 95% CI = [- 0.34,0.15]; P = 0.43）的血清硬化素水平与HC患者无显著差异。结论。AS和RA患者血清硬化蛋白水平与HC无明显差异，提示硬化蛋白可能与AS和RA的发展无关。
Objective. Current studies of serum sclerostin levels in AS and RA patients are inconsistent. This meta-analysis was performed to identify the association of serum sclerostin level with AS and RA patients. Methods. Embase, PubMed, MEDLINE, and Cochrane Library databases (up to 25 January 2017) were used to collect all relevant published articles. Studies were pooled and standard mean difference (SMD) with 95% confidence interval (CI) was calculated. All data analyses were performed using RevMan 5.3. Results. Totally eight studies of AS including 420 AS patients and 317 healthy controls (HC) and three studies of RA including 145 RA patients and 127 HC were finally included in this meta-analysis. The results revealed that the serum sclerostin levels in both AS patients (SMD = −0.14; 95% CI = [−0.39,0.11]; P = 0.28) and RA patients (SMD = −0.10; 95% CI = [−0.34,0.15]; P = 0.43) were not significantly different from those in HC. Conclusion. The difference of serum sclerostin levels in AS and RA patients was not significantly different from HC, indicating that the sclerostin may not associate with the development of AS and RA.